Loading...
XCSE
HLUN A
Market cap5.35bUSD
Dec 05, Last price  
34.85DKK
1D
0.72%
1Q
3.26%
Name

H. Lundbeck

Chart & Performance

D1W1MN
XCSE:HLUN A chart
P/E
11.00
P/S
1.57
EPS
3.17
Div Yield, %
2.02%
Shrs. gr., 5y
4.52%
Rev. gr., 5y
4.86%
Revenues
22.00b
+10.51%
9,069,800,0009,221,000,00010,984,900,00011,281,800,00013,747,000,00014,765,000,00016,007,000,00014,802,000,00015,258,000,00013,468,000,00014,594,000,00015,634,000,00017,234,000,00017,875,000,00017,358,000,00017,667,000,00016,299,000,00018,246,000,00019,912,000,00022,004,000,000
Net income
3.14b
+37.25%
2,923,400,0002,158,700,0003,353,500,0002,736,200,0002,007,000,0002,466,000,0002,282,000,0001,107,000,000855,000,000-153,000,000-5,694,000,0001,211,000,0002,624,000,0003,907,000,0002,667,000,0001,581,000,0001,318,000,0001,916,000,0002,290,000,0003,143,000,000
CFO
3.33b
-18.48%
2,071,500,0001,394,000,0002,704,800,0002,780,200,0003,034,000,0003,265,000,0003,624,000,0002,112,000,0003,760,000,0001,610,000,000197,000,0003,126,000,0004,045,000,0005,981,000,0002,609,000,0003,837,000,0002,272,000,0003,519,000,0004,080,000,0003,326,000,000
Dividend
Mar 21, 20240.7 DKK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.
URL
https://www.lundbeck.com/
IPO date
Jan 01, 1999
Employees
5,600
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT